Vitrafy Life Sciences Limited | Level 11, 385 Bourke Street, Melbourne, 3000 | ABN 48 622 720 254 W www.vitrafy.com | E [email protected] ASX ANNOUNCEMENT 16 October 2026 2026 Notice of Annual General Meeting Vitrafy Life Sciences Limited ("Vitrafy" or "Company") (ASX: VFY) attaches the...
2026 Notice of Annual General Meeting
Filed with ASX · · 33 pages · English
Summary by 6ix AI
This filing is the Notice of Annual General Meeting for Vitrafy Life Sciences Ltd., detailing the agenda and resolutions to be voted on during the meeting. The meeting is scheduled to be held as a hybrid event, allowing shareholders to attend either in person or online. Key resolutions include the adoption of the remuneration report, election of directors, and approval of a placement facility. Voting restrictions apply to certain resolutions, particularly those involving key management personnel.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Vitrafy Life Sciences Ltd. on 6ix
Earlier from Vitrafy Life Sciences
- Investor Roadshow Presentation
- Change to CEO Remuneration and Employment Terms
- Vitrafy enters partnership with Versiti Blood Health
- S&P DJI Announces September 2026 Quarterly Rebalance
- Vitrafy enters U.S. Cell & Gene Therapy Market
Later from Vitrafy Life Sciences
- Appointment of Chief Financial Officer
- Application for quotation of securities - VFY
- Vitrafy Q1 FY27 Investor Briefing
- Q1 FY27 Quarterly Activities Report and Appendix 4C
- Quarterly Investor Briefing Presentation
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences